Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000;14(3):120-4.
doi: 10.1002/(sici)1098-2825(2000)14:3<120::aid-jcla6>3.0.co;2-#.

Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month

A Magalini  1 , M Puoti, V Putzolu, E Quiros-Roldan, M A Forleo, S Rossi, S Zaltron, A Spinetti, B Zanini, A Zonaro, R Solfrini, G Carosi
Affiliations
Clinical Trial

Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month

A Magalini et al. J Clin Lab Anal. 2000.

Abstract

Early monitoring of HCVRNA during interferon treatment may allow clinicians to obtain important information that could help them to adopt therapeutic decisions in individual cases. The hepatitis C virus infection is highly dynamic and a daily high dose of IFN may induce a decline of viremia of 95+/-10% of baseline value after 24 to 48 hours of treatment. The importance of this early antiviral efficacy has not been understood. We have measured HCVRNA levels in 47 patients with chronic hepatitis C infection during interferon treatment to study HCVRNA kinetics and evaluate the predictive value of the early decay of viremia on the virological response after one month of treatment. Sixty percent of treated patients showed early virological response (EVR) and it was significantly associated with low HCVRNA levels and a genotype other than 1b. Finally, the absence of an 85% decline in HCVRNA levels after 3 days of treatment observed in 11 out of 45 patients (24%) was an absolute and very early predictor of the absence of EVR in the study population.

PubMed Disclaimer

References

    1. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999;30: 956–961. - PubMed
    1. Davis GL. Prediction of response to interferon treatment of chronic viral hepatitis. J Hepatol 1994;21:1–3. - PubMed
    1. Tsubota A, Chayama K, Ikeda K, Yasuji A, et al. Factors predictive of response to interferon‐alpha therapy in hepatitis C virus infection. Hepatol 1994;19:1088–1094. - PubMed
    1. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon‐alpha therapy: relationship to genotypes of HCV. Hepatol 1992;16:293–299. - PubMed
    1. Lam NP, Neuman A, Gretch D, Wiley T, Perelson A, Layden T. Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997;26:226–231. - PubMed

Publication types